Approaches to the Diagnosis and Management of Ovarian Cancer in Pregnancy

References

• Mancari R, Tomasi-Cont N, Sarno MA, et al. Treatment options for pregnant women with ovarian tumors. Int J Gynecol Cancer. 2014;24(6):967–972. Lippincott Williams and Wilkins. doi:10.1097/IGC.000000000000016124978707
   PubMed Web of Science ®Google Scholar
• Zhao XY, Huang HF, Lian LJ, Lang JH. Ovarian cancer in pregnancy: a clinicopathologic analysis of 22 cases and review of the literature. Int J Gynecol Cancer. 2006;16(1):8–15. doi:10.1111/j.1525-1438.2006.00422.x16445603
   PubMed Web of Science ®Google Scholar
• Leiserowitz GS, Xing G, Cress R, Brahmbhatt B, Dalrymple JL, Smith LH. Adnexal masses in pregnancy: how often are they malignant? Gynecol Oncol. 2006;101(2):315–321. doi:10.1016/j.ygyno.2005.10.02216310839
   PubMed Web of Science ®Google Scholar
• Aggarwal P, Kehoe S. Ovarian tumours in pregnancy: a literature review. Eur J Obstet Gynecol Reprod Biol. 2011;155(2):119–124. Elsevier Ireland Ltd. doi:10.1016/j.ejogrb.2010.11.02321194826
   PubMed Web of Science ®Google Scholar
• Amant F, Halaska MJ, Fumagalli M, et al. Gynecologic cancers in pregnancy: guidelines of a second international consensus meeting. Int J Gynecol Cancer. 2014;24(3):394–403. Lippincott Williams and Wilkins. doi:10.1097/IGC.000000000000006224445819
   PubMed Web of Science ®Google Scholar
• Han SN, Kesic VI, Van Calsteren K, Petkovic S, Amant F. Cancer in pregnancy: a survey of current clinical practice. Eur J Obstet Gynecol Reprod Biol. 2013;167(1):18–23. doi:10.1016/j.ejogrb.2012.10.02623182070
   PubMed Web of Science ®Google Scholar
• Grimm D, Woelber L, Trillsch F, Amsberg GK, Mahner S. Clinical management of epithelial ovarian cancer during pregnancy. Eur J Cancer. 2014;50(5):963–971. doi:10.1016/j.ejca.2013.12.02024462638
   PubMed Web of Science ®Google Scholar
• Lockley M, Stoneham SJ, Olson TA. Ovarian cancer in adolescents and young adults. Pediatr Blood Cancer. 2019;66(3):e27512. doi:10.1002/pbc.2751230350916
   PubMed Web of Science ®Google Scholar
• Ishioka SI, Hayashi T, Endo T, Baba T, Honma H, Saito T. Advanced epithelial ovarian carcinoma during pregnancy. Int J Clin Oncol. 2007;12(5):375–378. doi:10.1007/s10147-007-0655-017929120
   PubMed Web of Science ®Google Scholar
• Minig L, Otaño L, Diaz-Padilla I, Alvarez Gallego R, Patrono MG, Valero De Bernabé J. Therapeutic management of epithelial ovarian cancer during pregnancy. Clin Transl Oncol. 2013;15(4):259–264. doi:10.1007/s12094-012-0963-323180347
   PubMed Web of Science ®Google Scholar
• Van Calsteren K, Heyns L, De Smet F, et al. Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. J Clin Oncol. 2010;28(4):683–689. doi:10.1200/JCO.2009.23.280119841323
   PubMed Web of Science ®Google Scholar
• Morice P, Uzan C, Gouy S, Verschraegen C, Haie-Meder C. Gynaecological cancers in pregnancy. Lancet. 2012;379(9815):558–569. Lancet Publishing Group. doi:10.1016/S0140-6736(11)60829-522325661
   PubMed Web of Science ®Google Scholar
• Cavaco-Gomes J, Jorge Moreira C, Rocha A, Mota R, Paiva V, Costa A. Investigation and management of adnexal masses in pregnancy. Scientifica. 2016;2016.
   PubMedGoogle Scholar
• Guidelines for diagnostic imaging during pregnancy and lactation | ACOG. [Online]. Available from: https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/10/guidelines-for-diagnostic-imaging-during-pregnancy-and-lactation. Accessed 1008, 2020.
   Google Scholar
• Yen CF, Lin S-L, Murk W, et al. Risk analysis of torsion and malignancy for adnexal masses during pregnancy. Fertil Steril. 2009;91(5):1895–1902. doi:10.1016/j.fertnstert.2008.02.01418359024
   PubMed Web of Science ®Google Scholar
• Marret H, Lhommé C, Lecuru F, et al. Guidelines for the management of ovarian cancer during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2010;149(1):18–21. Elsevier Ireland Ltd. doi:10.1016/j.ejogrb.2009.12.00120042265
   PubMed Web of Science ®Google Scholar
• Kanal E, Barkovich AJ, Bell C, et al. ACR guidance document on MR safe practices: 2013. J Magn Reson Imaging. 2013;37(3):501–530. doi:10.1002/jmri.2401123345200
   PubMed Web of Science ®Google Scholar
• Lu J, Zheng Z, Zhang Q, et al. Measurement of HE4 and CA125 and establishment of reference intervals for the ROMA index in the sera of pregnant women. J Clin Lab Anal. 2018;32(5):e22368. doi:10.1002/jcla.2236829194801
   PubMed Web of Science ®Google Scholar
• Moore RG, Miller MC, Eklund EE, Lu KH, Bast RC, Lambert-Messerlian G. Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. Am J Obstet Gynecol. 2012;206(4):349.e1–349.e7. doi:10.1016/j.ajog.2011.12.028
   Web of Science ®Google Scholar
• Makkonen M, Penttilä IM, Castrén O. Serum lactic acid dehydrogenase and isoenzymes during pregnancy and labor. Acta Obstet Gynecol Scand. 1980;59(2):97–101. doi:10.3109/000163480091546227405558
   PubMed Web of Science ®Google Scholar
• Yoshimura T, Takemori K, Okazaki T, Suzuki A. Serum lactic dehydrogenase and its isoenzymes in patients with ovarian dysgerminoma. Int J Gynecol Obstet. 1988;27(3):459–465. doi:10.1016/0020-7292(88)90131-2
   PubMed Web of Science ®Google Scholar
• Horbelt D, Delmore J, Meisel R, Cho S, Roberts D, Logan D. Mixed germ cell malignancy of the ovary concurrent with pregnancy. Obstet Gynecol. 1994;4(84).
   Google Scholar
• Zemlickis D, Lishner M, Degendorfer P, Panzarella T, Sutcliffe SB, Koren G. Fetal outcome after in utero exposure to cancer chemotherapy. Arch Intern Med. 1992;152(3):573. doi:10.1001/archinte.1992.004001500930171546920
   PubMedGoogle Scholar
• Cole LA. HCG variants, the growth factors which drive human malignancies. Am J Cancer Res. 2012;2(1).
   PubMed Web of Science ®Google Scholar
• Liu N, Peng S-M, Zhan G-X, et al. Human chorionic gonadotropin β regulates epithelial-mesenchymal transition and metastasis in human ovarian cancer. Oncol Rep. 2017;38(3):1464–1472. doi:10.3892/or.2017.581828713970
   PubMed Web of Science ®Google Scholar
• Muttukrishna S. Role of inhibin in normal and high-risk pregnancy. Semin Reprod Med. 2004;22(3):227–234. doi:10.1055/s-2004-83189815319825
   PubMed Web of Science ®Google Scholar
• Fowler PA, Evans LW, Groome NP, Templeton A, Knight PG. A longitudinal study of maternal serum inhibin-A inhibin-B, activin-A activin-AB, pro-αC and follistatin during pregnancy. Hum Reprod. 1998;13(12):3530–3536. doi:10.1093/humrep/13.12.35309886545
   PubMed Web of Science ®Google Scholar
• La Marca A, Broekmans FJ, Volpe A, Fauser BC, Macklon NS. Anti-Mullerian hormone (AMH): what do we still need to know? Hum Reprod. 2009;24(9):2264–2275. doi:10.1093/humrep/dep21019520713
   PubMed Web of Science ®Google Scholar
• La Marca A, Giulini S, Orvieto R, De Leo V, Volpe A. Anti-Müllerian hormone concentrations in maternal serum during pregnancy. Hum Reprod. 2005;20(6):1569–1572. doi:10.1093/humrep/deh81915734752
   PubMed Web of Science ®Google Scholar
• Agarwal N, Kriplani PA, Bhatla N, Gupta A. Management and outcome of pregnancies complicated with adnexal masses. Arch Gynecol Obstet. 2003;267(3):148–152. doi:10.1007/s00404-001-0287-y12580154
   PubMedGoogle Scholar
• Leiserowitz GS. Managing ovarian masses during pregnancy. Obstet Gynecol Surv. 2006;61(7):463–470. doi:10.1097/01.ogx.0000224614.51356.b716787549
   PubMed Web of Science ®Google Scholar
• Horowitz NS. Management of adnexal masses in pregnancy. Clin Obstet Gynecol. 2011;54(4):519–527. doi:10.1097/GRF.0b013e318236c58322031242
   PubMed Web of Science ®Google Scholar
• Pearl J, Price R, Richardson W, Fanelli R. Guidelines for diagnosis, treatment, and use of laparoscopy for surgical problems during pregnancy. Surg Endoscopy. 2011;25:3479–3492. doi:10.1007/s00464-011-1927-3
   PubMed Web of Science ®Google Scholar
• Munnell EW. Is conservative therapy ever justified in Stage I (IA) cancer of the ovary? Am J Obstet Gynecol. 1969;103(5):641–653. doi:10.1016/0002-9378(69)90561-44304017
   PubMed Web of Science ®Google Scholar
• Kajiyama H, Shibata K, Suzuki S, et al. Fertility-sparing surgery in young women with invasive epithelial ovarian cancer. Eur J Surg Oncol. 2010;36(4):404–408. doi:10.1016/j.ejso.2010.01.00520116965
   PubMed Web of Science ®Google Scholar
• Satoh T, Tsuda H, Kanato K, et al. A non-randomized confirmatory study regarding selection of fertility-sparing surgery for patients with epithelial ovarian cancer: Japan Clinical Oncology Group Study (JCOG1203). Jpn J Clin Oncol. 2015;45:6. doi:10.1093/jjco/hyv032
   Web of Science ®Google Scholar
• Fruscio R, Corso S, Ceppi L, et al. Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series. Ann Oncol. 2013;24(1):138–144. doi:10.1093/annonc/mds24122945381
   PubMed Web of Science ®Google Scholar
• Smith HO, Berwick M, Verschraegen CF, et al. Incidence and survival rates for female malignant germ cell tumors. Obstet Gynecol. 2006;107(5):1075–1085. doi:10.1097/01.AOG.0000216004.22588.ce16648414
   PubMed Web of Science ®Google Scholar
• Morice P, Denschlag D, Rodolakis A, et al. Recommendations of the fertility task force of the European Society of Gynecologic Oncology about the conservative management of ovarian malignant tumors. Int J Gynecol Cancer. 2011;21:5. doi:10.1097/IGC.0b013e31821bec6b
   Web of Science ®Google Scholar
• Satoh T, Aoki Y, Kasamatsu T, et al. Administration of standard-dose BEP regimen (bleomycin + etoposide + cisplatin) is essential for treatment of ovarian yolk sac tumour. Eur J Cancer. 2015;51(3):340–351. doi:10.1016/j.ejca.2014.12.00425559616
   PubMed Web of Science ®Google Scholar
• Chatziioannidou K, Botsikas D, Tille JC, Dubuisson J. Preservation of fertility in non-Peutz- Jegher syndrome-associated ovarian sex cord tumour. BMJ Case Rep. 2015, 2015. doi:10.1136/bcr-2014-207841
   PubMedGoogle Scholar
• Stavrakis T, Kalogiannidis I, Petousis S, et al. Fertility-sparing management and obstetric outcomes in a 20-year-old patient with a Sertoli-Leydig cell tumor of the ovary: a case report and review of the literature. Oncol Lett. 2016;12:2. doi:10.3892/ol.2016.4695
   Web of Science ®Google Scholar
• Koren G. Fetal risks of maternal pharmacotherapy: identifying signals. Handb Exp Pharmacol. 2011;205.
   Google Scholar
• Schaefer C. Drug safety in pregnancy—a particular challenge. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2018;61:9.
   Web of Science ®Google Scholar
• Amant F, Loibl S, Neven P, Van Calsteren K. Breast cancer in pregnancy. Lancet. 2012;379(9815):570–579. Lancet Publishing Group. doi:10.1016/S0140-6736(11)61092-122325662
   PubMed Web of Science ®Google Scholar
• Halaska MJ, Komar M, Vlk R, et al. A pilot study on peak systolic velocity monitoring of fetal anemia after administration of chemotherapy during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2014;174(1):76–79. doi:10.1016/j.ejogrb.2013.12.02124439719
   PubMed Web of Science ®Google Scholar
• Tetro N, Moushaev S, Rubinchik-Stern M, Eyal S. The placental barrier: the gate and the fate in drug distribution. Pharm Res. 2018;35:4. doi:10.1007/s11095-017-2286-0
   Web of Science ®Google Scholar
• Berveiller P, Mir O. Taxanes during pregnancy: probably safe, but still to be optimized. Oncology. 2012;83:4.
   Web of Science ®Google Scholar
• Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol. 2004;5:5. doi:10.1016/S1470-2045(04)01466-414723225
   PubMed Web of Science ®Google Scholar
• Ruiz Ramos J, Roma E, Palomar L, Poveda JL. Paclitaxel and carboplatin treatment for advanced ovarian cancer during pregnancy. Chemotherapy. 2014;59(5):344–345. doi:10.1159/000360691
   Web of Science ®Google Scholar
• Slimano F, Baudouin A, Zerbit J, et al. Cancer, immune suppression and coronavirus disease-19 (COVID-19): need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines). Cancer Treat Rev. 2020;88:102063. doi:10.1016/j.ctrv.2020.10206332623296
   PubMed Web of Science ®Google Scholar
• Shah R, Xia C, Krailo M, et al. Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults? Gynecol Oncol. 2018;150(2):253–260. doi:10.1016/j.ygyno.2018.05.02529884437
   PubMed Web of Science ®Google Scholar
• Ghaemmaghami F, Abbasi F, Abadi AGN. A favorable maternal and neonatal outcome following chemotherapy with etoposide, bleomycin, and cisplatin for management of grade 3 immature teratoma of the ovary. J Gynecol Oncol. 2009;20(4):257. doi:10.3802/jgo.2009.20.4.25720041106
   PubMed Web of Science ®Google Scholar
• Cardonick E, Usmani A, Ghaffar S. Perinatal outcomes of a pregnancy complicated by cancer, including neonatal follow-up after in utero exposure to chemotherapy: results of an international registry. Am J Clin Oncol Cancer Clin Trials. 2010;33(3).
   PubMed Web of Science ®Google Scholar
• Han JY, Nava-Ocampo AA, Kim TJ, Shim JU, Park CT. Pregnancy outcome after prenatal exposure to bleomycin, etoposide and cisplatin for malignant ovarian germ cell tumors: report of 2 cases. Reprod Toxicol. 2005;19(4):557–561. doi:10.1016/j.reprotox.2004.11.00215749271
   PubMed Web of Science ®Google Scholar
• Amant F, Berveiller P, Boere IA, et al. Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting. Ann Oncol. 2019;30:10. doi:10.1093/annonc/mdz22830462161
   PubMed Web of Science ®Google Scholar
• Alfasi A, Ben-Aharon I. Breast cancer during pregnancy—current paradigms, paths to explore. Cancers. 2019;11:11. doi:10.3390/cancers11111669
   Web of Science ®Google Scholar
• Boere I, Lok C, Vandenbroucke T, Amant F. Cancer in pregnancy: safety and efficacy of systemic therapies. Curr Opin Oncol. 2017;29:5. doi:10.1097/CCO.0000000000000386
   Web of Science ®Google Scholar
• Cordeiro CN, Gemignani ML. Gynecologic malignancies in pregnancy: balancing fetal risks with oncologic safety. Obstet Gynecol Surv. 2017;72(3):184–193. doi:10.1097/OGX.000000000000040728304416
   PubMed Web of Science ®Google Scholar